TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Study of Redirected Autologous T Cells Transduced to Express A CD20-Specific Chimeric Immunoreceptor in Patient With Chemotherapy Resistant or Refractory CD20+ Leukemia and Lymphoma
Brief Summary: RATIONALE: Placing a gene that has been created in the laboratory into white blood cells may make the body build an immune response to kill cancer cells.

PURPOSE: This clinical trial is studying genetically engineered lymphocyte therapy in treating patients with B-cell leukemia or lymphoma that is resistant or refractory to chemotherapy.


Options:
A: Arm Label: Lisocabtagene maraleucel; Type: EXPERIMENTAL; Interventions: Biological: lisocabtagene maraleucel | Intervention Type: BIOLOGICAL; Name: lisocabtagene maraleucel; Assigned to Arm(s): Lisocabtagene maraleucel
B: Arm Label: Single dose of CTL019; Type: EXPERIMENTAL; Interventions: Biological: CTL019 | Intervention Type: BIOLOGICAL; Name: CTL019; Assigned to Arm(s): Single dose of CTL019
C: Arm Label: anti-CD20-CAR T cell; Type: EXPERIMENTAL; Interventions: Biological: anti-CD20-CAR vector-transduced autologous T cells, Other: genetically engineered lymphocyte therapy | Intervention Type: BIOLOGICAL; Name: anti-CD20-CAR vector-transduced autologous T cells; Assigned to Arm(s): anti-CD20-CAR T cell | Intervention Type: OTHER; Name: genetically engineered lymphocyte therapy; Assigned to Arm(s): anti-CD20-CAR T cell
D: Arm Label: CD19-CART01; Type: EXPERIMENTAL; Interventions: Biological: CD19-CAR T cell | Intervention Type: BIOLOGICAL; Name: CD19-CAR T cell; Assigned to Arm(s): CD19-CART01

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Mirror Therapy in Stroke Patients With Unilateral Neglect - A Randomized Controlled Trial
Brief Summary: Hemi spatial neglect, or the tendency to ignore stimuli originating in a portion of the environment contra lateral to a cerebral lesion, can be a major source of functional handicap after stroke. The currently available treatments for unilateral neglect are scanning training, visual cuing approaches, limb activation strategies, visual imagery, tactile stimulation, prisms and sustained attention training.Mirror therapy improves the hand function in sub-acute stroke.

Hypothesis: To evaluate the effectiveness of Mirror therapy in the management of stroke patients with unilateral neglect.


Options:
A: Arm Label: Arm A Anodal tDCS and prismatic adaptation; Type: EXPERIMENTAL; Interventions: Device: transcranial direct current stimulation (tDCS) | Arm Label: Arm B: control; Type: PLACEBO_COMPARATOR; Interventions: Device: Control: placebo stimulation | Intervention Type: DEVICE; Name: transcranial direct current stimulation (tDCS); Assigned to Arm(s): Arm A Anodal tDCS and prismatic adaptation | Intervention Type: DEVICE; Name: Control: placebo stimulation; Assigned to Arm(s): Arm B: control
B: Intervention Type: OTHER; Name: Visumotor Upper Extremity Training; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: Anodal/Sham tDCS; Assigned to Arm(s): N/A
C: Arm Label: Mirror therapy; Type: EXPERIMENTAL; Interventions: Other: Mirror therapy | Arm Label: Control group; Type: SHAM_COMPARATOR; Interventions: Other: Control group | Intervention Type: OTHER; Name: Mirror therapy; Assigned to Arm(s): Mirror therapy | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): Control group
D: Arm Label: Mirror therapy with tDCS; Type: EXPERIMENTAL; Interventions: Behavioral: Mirror Therapy with tDCS | Arm Label: Mirror Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mirror Therapy | Arm Label: Control Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control Intervention | Arm Label: Mirror Therapy with sham-tDCS; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mirror Therapy with sham-tDCS | Intervention Type: BEHAVIORAL; Name: Mirror Therapy with tDCS; Assigned to Arm(s): Mirror therapy with tDCS | Intervention Type: BEHAVIORAL; Name: Mirror Therapy with sham-tDCS; Assigned to Arm(s): Mirror Therapy with sham-tDCS | Intervention Type: BEHAVIORAL; Name: Mirror Therapy; Assigned to Arm(s): Mirror Therapy | Intervention Type: BEHAVIORAL; Name: Control Intervention; Assigned to Arm(s): Control Intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Artemisinin-resistant Plasmodium Falciparum Malaria in Cambodia
Brief Summary: Background:

- Artemisinin-based combination therapies (ACTs) are the first-line treatments for malaria. ACTs are highly effective, but malaria caused by the Plasmodium falciparum parasite is becoming resistant to some ACTs. ACT-resistant malaria has shown up in some parts of Cambodia, but not yet in other parts of the country. This has been shown by treating patients with ACTs, checking the amount of parasites in the patient s blood every 6 hours, and calculating the rate of parasite clearance. The parasite clearance rate in response to ACTs is getting slower in western Cambodia and may be the first sign of ACT resistance. Researchers want to study how effective ACTs are in different regions of Cambodia. This study will look at the extent of ACT resistance and how widespread ACT-resistant malaria has become.

Objectives:

- To compare the prevalence of ACT-resistant malaria in western, northern and eastern Cambodia.

Eligibility:

- Individuals between 2 and 65 years of age who have uncomplicated Plasmodium falciparum malaria and have not taken any antimalarial drugs for their symptoms in the previous 7 days.

Design:

* Participants will be recruited from clinics and hospitals in three Cambodian provinces.
* Participants will be informed about the study and their consent to participate in the study will be obtained.
* A venous blood sample will be obtained from patients before treatment and used for laboratory experiments to measure parasite and patient factors that might affect the parasite clearance rate.
* Participants with malaria will be treated with dihydroartemisinin-piperaquine (DHA-PPQ), the standard first-line treatment for malaria in Cambodia.
* Treatment will be monitored with frequent blood samples obtained from a finger prick. The amount of malaria parasites in each blood sample will be counted and followed until they are no longer detectable.
* Participants will have weekly follow-up visits for up to 9 weeks. Finger-prick blood samples will be taken at each visit to see if the parasites reappear after treatment with ACT.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Seasonal IPT in children - Sulfadoxine-pyrimethamine | Intervention Type: DRUG; Name: Seasonal IPT in children - Sulfadoxine-pyrimethamine; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Sulfadoxine-pyrimethamine used for IPTi, Drug: IPTi | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine used for IPTi; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: IPTi; Assigned to Arm(s): 1
C: N/A
D: Intervention Type: DRUG; Name: Sulfadoxine pyrimethamine; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
Brief Summary: The purpose of this study is to determine if KRX-0502 (ferric citrate) is a safe and effective treatment for the management of serum phosphorus levels and iron deficiency in anemic chronic kidney disease (CKD) stage 3-5 subjects not on dialysis. Total length of treatment is approximately 12 weeks.


Options:
A: Arm Label: Ferric Citrate; Type: EXPERIMENTAL; Interventions: Drug: Ferric Citrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ferric Citrate; Assigned to Arm(s): Ferric Citrate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: MCI-196 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: MCI-196; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: Sevelamer; Type: OTHER; Interventions: Drug: Sevelamer, Drug: calcium acetate | Arm Label: calcium acetate; Type: OTHER; Interventions: Drug: calcium acetate | Intervention Type: DRUG; Name: Sevelamer; Assigned to Arm(s): Sevelamer | Intervention Type: DRUG; Name: calcium acetate; Assigned to Arm(s): Sevelamer, calcium acetate
D: Arm Label: 900 mg Phosphate Diet-LC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lanthanum Carbonate, Other: 900 mg Phosphate Diet | Arm Label: Ad Libitum Diet-LC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lanthanum Carbonate, Other: Ad Libitum Diet | Arm Label: 900 mg Phosphate Diet-LC Placebo; Type: ACTIVE_COMPARATOR; Interventions: Other: 900 mg Phosphate Diet, Drug: LC Placebo | Arm Label: Ad Libitum Diet-LC Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: LC Placebo, Other: Ad Libitum Diet | Intervention Type: DRUG; Name: Lanthanum Carbonate; Assigned to Arm(s): 900 mg Phosphate Diet-LC, Ad Libitum Diet-LC | Intervention Type: OTHER; Name: 900 mg Phosphate Diet; Assigned to Arm(s): 900 mg Phosphate Diet-LC, 900 mg Phosphate Diet-LC Placebo | Intervention Type: DRUG; Name: LC Placebo; Assigned to Arm(s): 900 mg Phosphate Diet-LC Placebo, Ad Libitum Diet-LC Placebo | Intervention Type: OTHER; Name: Ad Libitum Diet; Assigned to Arm(s): Ad Libitum Diet-LC, Ad Libitum Diet-LC Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2/3, Multi-Center, Open Label Study of Efficacy, Safety, and Pharmacokinetics of PEGylated Recombinant Factor VIII (BAX 855) Administered for Prophylaxis and Treatment of Bleeding in Previously Treated Patients With Severe Hemophilia A
Brief Summary: To assess efficacy and safety, including immunogenicity of BAX 855 administered as prophylaxis and as on-demand therapy in adult and adolescent (12-65 years) previously treated patients (PTPs) with severe hemophilia A To determine the pharmacokinetic (PK) parameters of BAX 855.


Options:
A: Arm Label: Prophylaxis; Type: EXPERIMENTAL; Interventions: Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method, Biological: PEGylated Recombinant Factor VIII | Arm Label: On-demand; Type: EXPERIMENTAL; Interventions: Biological: PEGylated Recombinant Factor VIII | Intervention Type: BIOLOGICAL; Name: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method; Assigned to Arm(s): Prophylaxis | Intervention Type: BIOLOGICAL; Name: PEGylated Recombinant Factor VIII; Assigned to Arm(s): Prophylaxis | Intervention Type: BIOLOGICAL; Name: PEGylated Recombinant Factor VIII; Assigned to Arm(s): Prophylaxis | Intervention Type: BIOLOGICAL; Name: PEGylated Recombinant Factor VIII; Assigned to Arm(s): On-demand
B: Arm Label: Prophylaxis; Type: EXPERIMENTAL; Interventions: Biological: rIX-FP | Arm Label: On-demand; Type: EXPERIMENTAL; Interventions: Biological: rIX-FP | Intervention Type: BIOLOGICAL; Name: rIX-FP; Assigned to Arm(s): On-demand, Prophylaxis
C: Arm Label: Fixed Weekly Interval; Type: EXPERIMENTAL; Interventions: Drug: Factor IX (rFIXFc), Drug: rFIX | Arm Label: Individualized Interval; Type: EXPERIMENTAL; Interventions: Drug: Factor IX (rFIXFc) | Arm Label: On Demand; Type: EXPERIMENTAL; Interventions: Drug: Factor IX (rFIXFc) | Arm Label: Surgery; Type: EXPERIMENTAL; Interventions: Drug: Factor IX (rFIXFc) | Intervention Type: DRUG; Name: Factor IX (rFIXFc); Assigned to Arm(s): Fixed Weekly Interval, Individualized Interval, On Demand, Surgery | Intervention Type: DRUG; Name: rFIX; Assigned to Arm(s): Fixed Weekly Interval
D: N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2/3, Multi-Center, Open Label Study of Efficacy, Safety, and Pharmacokinetics of PEGylated Recombinant Factor VIII (BAX 855) Administered for Prophylaxis and Treatment of Bleeding in Previously Treated Patients With Severe Hemophilia A
Brief Summary: To assess efficacy and safety, including immunogenicity of BAX 855 administered as prophylaxis and as on-demand therapy in adult and adolescent (12-65 years) previously treated patients (PTPs) with severe hemophilia A To determine the pharmacokinetic (PK) parameters of BAX 855.


Options:
A: Arm Label: Fixed Weekly Interval; Type: EXPERIMENTAL; Interventions: Drug: Factor IX (rFIXFc), Drug: rFIX | Arm Label: Individualized Interval; Type: EXPERIMENTAL; Interventions: Drug: Factor IX (rFIXFc) | Arm Label: On Demand; Type: EXPERIMENTAL; Interventions: Drug: Factor IX (rFIXFc) | Arm Label: Surgery; Type: EXPERIMENTAL; Interventions: Drug: Factor IX (rFIXFc) | Intervention Type: DRUG; Name: Factor IX (rFIXFc); Assigned to Arm(s): Fixed Weekly Interval, Individualized Interval, On Demand, Surgery | Intervention Type: DRUG; Name: rFIX; Assigned to Arm(s): Fixed Weekly Interval
B: Arm Label: Prophylaxis; Type: EXPERIMENTAL; Interventions: Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method, Biological: PEGylated Recombinant Factor VIII | Arm Label: On-demand; Type: EXPERIMENTAL; Interventions: Biological: PEGylated Recombinant Factor VIII | Intervention Type: BIOLOGICAL; Name: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method; Assigned to Arm(s): Prophylaxis | Intervention Type: BIOLOGICAL; Name: PEGylated Recombinant Factor VIII; Assigned to Arm(s): Prophylaxis | Intervention Type: BIOLOGICAL; Name: PEGylated Recombinant Factor VIII; Assigned to Arm(s): Prophylaxis | Intervention Type: BIOLOGICAL; Name: PEGylated Recombinant Factor VIII; Assigned to Arm(s): On-demand
C: Arm Label: Prophylaxis; Type: EXPERIMENTAL; Interventions: Biological: rIX-FP | Arm Label: On-demand; Type: EXPERIMENTAL; Interventions: Biological: rIX-FP | Intervention Type: BIOLOGICAL; Name: rIX-FP; Assigned to Arm(s): On-demand, Prophylaxis
D: Arm Label: Group 1; Type: OTHER; Interventions: Genetic: Gene Transfer, Drug: scAAV2/8-LP1-hFIXco | Intervention Type: GENETIC; Name: Gene Transfer; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: scAAV2/8-LP1-hFIXco; Assigned to Arm(s): Group 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Psycho-educational Intervention to Improve Family Mental Health and Child Educational Outcomes Following Admission to PICU: A Pilot Study
Brief Summary: 1. Evaluate the feasibility and acceptability of an information based intervention delivered to parents following their child's admission to paediatric intensive care;
2. Evaluate the feasibility and acceptability of the study design and procedures;
3. Explore the effects of the intervention on parent and child psychological outcomes 3-6 months post discharge from PICU;
4. Explore the effects of parental stress experienced during PICU admission on the effectiveness of the intervention;
5. To provide data that, combined with results from other studies, could inform the sample size for a future multi-site RCT.


Options:
A: Arm Label: Prolonged Exposure (CBT); Type: EXPERIMENTAL; Interventions: Procedure: Cognitive Behavioral Therapy | Arm Label: Cognitive Therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Cognitive Therapy | Arm Label: SSRI (escitalopram); Type: EXPERIMENTAL; Interventions: Drug: Escitalopram | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Waiting List; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): Prolonged Exposure (CBT) | Intervention Type: PROCEDURE; Name: Cognitive Therapy; Assigned to Arm(s): Cognitive Therapy | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): SSRI (escitalopram) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Psycho-educational intervention; Type: EXPERIMENTAL; Interventions: Other: Psycho-education | Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Psycho-education; Assigned to Arm(s): Psycho-educational intervention
C: Arm Label: Discussion with nurse; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: ICU Diary; Type: EXPERIMENTAL; Interventions: Other: ICU Diary | Intervention Type: OTHER; Name: ICU Diary; Assigned to Arm(s): ICU Diary
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy, Behavioral: Motivational Interviewing, Drug: FDA-Approved Anti-Anxiety Medications | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Care Control | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: FDA-Approved Anti-Anxiety Medications; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Standard Care Control; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Investigation for Fractures of the Proximal Humerus in Elderly Patients. A Randomized Study of Two Surgical Treatments: Reverse Total Shoulder Arthroplasty Versus Angular Stable Device Philos
Brief Summary: To investigate the assumption that reversed shoulder prosthetic replacement will give a better functional outcome compared to open reduction and internal fixation with an angular stable plate in displaced proximal humeral fractures. Short name: The DelPhi trial.


Options:
A: Arm Label: Angular stable plate Philos; Type: ACTIVE_COMPARATOR; Interventions: Device: Reverse total shoulder arthroplasty | Arm Label: Reverse Total Shoulder Artroplasty; Type: EXPERIMENTAL; Interventions: Device: Reverse total shoulder arthroplasty | Intervention Type: DEVICE; Name: Reverse total shoulder arthroplasty; Assigned to Arm(s): Angular stable plate Philos, Reverse Total Shoulder Artroplasty
B: Arm Label: Telerehabilitation; Type: EXPERIMENTAL; Interventions: Other: Rehabilitation (Physiotherapy) | Arm Label: Face-to-face intervention in a clinic; Type: ACTIVE_COMPARATOR; Interventions: Other: Rehabilitation (Physiotherapy) | Intervention Type: OTHER; Name: Rehabilitation (Physiotherapy); Assigned to Arm(s): Face-to-face intervention in a clinic, Telerehabilitation
C: Arm Label: Operative treatment; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Operative treatment with Reversed Total Shoulder Prosthesis | Arm Label: Non-Operative treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Operative treatment with Reversed Total Shoulder Prosthesis; Assigned to Arm(s): Operative treatment
D: Arm Label: Conservative; Type: ACTIVE_COMPARATOR; Interventions: Other: Control group | Arm Label: Philos locking plate; Type: ACTIVE_COMPARATOR; Interventions: Device: Philos | Arm Label: Epoca prosthesis; Type: ACTIVE_COMPARATOR; Interventions: Device: Epoca | Intervention Type: DEVICE; Name: Philos; Assigned to Arm(s): Philos locking plate | Intervention Type: DEVICE; Name: Epoca; Assigned to Arm(s): Epoca prosthesis | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): Conservative

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy (NEURO-TTR Study)
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of inotersen given for 65 weeks in participants with Familial Amyloid Polyneuropathy (FAP).


Options:
A: Arm Label: Open-Label; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tafamidis | Intervention Type: DRUG; Name: Tafamidis; Assigned to Arm(s): Open-Label
B: Arm Label: Tafamidis - 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Tafamidis | Arm Label: Tafamidis - 80 mg; Type: EXPERIMENTAL; Interventions: Drug: Tafamidis | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tafamidis; Assigned to Arm(s): Tafamidis - 20 mg | Intervention Type: DRUG; Name: Tafamidis; Assigned to Arm(s): Tafamidis - 80 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: patisiran (ALN-TTR02); Type: ACTIVE_COMPARATOR; Interventions: Drug: patisiran (ALN-TTR02) | Arm Label: Sterile Normal Saline (0.9% NaCl); Type: PLACEBO_COMPARATOR; Interventions: Drug: Sterile Normal Saline (0.9% NaCl) | Intervention Type: DRUG; Name: patisiran (ALN-TTR02); Assigned to Arm(s): patisiran (ALN-TTR02) | Intervention Type: DRUG; Name: Sterile Normal Saline (0.9% NaCl); Assigned to Arm(s): Sterile Normal Saline (0.9% NaCl)
D: Arm Label: Inotersen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Inotersen | Arm Label: Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Inotersen; Assigned to Arm(s): Inotersen | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Fluoxetine for Motor Recovery After Acute Intracerebral Hemorrhage (FMRICH): a Randomised Placebo-controlled Trial
Brief Summary: This is a randomized, double-blind, placebo-controlled, multicenter clinical trial that will be carried out in Mexico. The purpose of this study is to test whether a 3-month treatment with fluoxetine enhances motor recovery in non-depressed patients with acute intracerebral hemorrhage.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: fluoxetine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
B: Arm Label: SSRI; Type: EXPERIMENTAL; Interventions: Drug: SSRI | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: SSRI; Assigned to Arm(s): SSRI | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Fluoxetine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluoxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Fluoxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Fluoxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D